PBS News

Expanded eligibility criteria for COVID-19 oral antiviral treatments, Paxlovid® (nirmatrelvir and ritonavir) and molnupiravir (Lagevrio®)

Page last updated: 10 July 2022

Commencing 11 July 2022, the eligibility criteria for COVID-19 oral antiviral treatments, nirmatrelvir and ritonavir (Paxlovid®) and molnupiravir (Lagevrio®), will be expanded.

New eligibility includes updated age limits and risk factors.

Additional information can be found in the following: